Clorox Q4 Misses, FY27 Guidance Trails Consensus as ERP and GOJO Headwinds Persist
CLX sits 17% above its 52-week low of $84.7.
Summary
Clorox's Q4 earnings missed sharply, with organic sales down 13% and adjusted EPS off 42%. FY27 guidance came in below consensus, reflecting ongoing cost pressures and a slow recovery from ERP and acquisition disruptions.
Key Events · Earnings and Guidance · CLX
-
Q4 Earnings Miss
Q4 diluted EPS of $1.34 missed expectations, down 50% year over year, as organic sales fell 13% due to lapping ERP transition shipments and GOJO integration costs.
-
Full-Year FY26 Decline
FY26 adjusted EPS of $5.53 was down 28% year over year, with net sales down 5% to $6.72B, driven by an ERP-related inventory drawdown and higher costs.
-
FY27 Guidance Below Consensus
FY27 adjusted EPS guidance of $5.70–$6.00 (midpoint $5.85) came in below the pre-release consensus of ~$6.10, reflecting persistent inflationary and mix headwinds.
-
GOJO Integration Costs
The GOJO acquisition added $0.36 to FY26 adjusted EPS headwinds, with another $0.29 expected in FY27, weighing on near-term profitability.
Analysis · CLX · Industrial Applications And Services
A steep 50% decline in Q4 diluted EPS to $1.34 fell short of expectations, as organic sales dropped 13%—a result of lapping prior ERP transition shipments and absorbing GOJO integration costs. For the full year, adjusted EPS of $5.53 was down 28%. The FY27 outlook points to a recovery with adjusted EPS of $5.70–$6.00, yet the midpoint of $5.85 sits below the pre-release consensus of roughly $6.10, signaling that margin pressure from inflation and mix headwinds will persist. Together, the results and guidance highlight the near-term drag from the GOJO acquisition and ERP transition, even as management emphasizes a stronger foundation for long-term growth.
How filings like this one have moved
In the 30 days to Oct 13, 2026, 29.1% of the 1502 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CLX was trading at $99.36 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $11.9B. The 52-week trading range was $84.70 to $128.90. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.